Tumor News and Research

RSS

Loyola and Notre Dame researchers report promising new approaches to treating cancer

Promising new approaches to treating cancer were reported during a recent meeting of researchers from Loyola University Chicago and the University of Notre Dame.

12 Nov 2015

Moffitt Cancer Center study finds link between common gene mutations and tumor immune surveillance

Learning if a lung cancer patient has genetic mutations can help oncologists determine the best approach to treatment. There are four gene mutations (KRAS, TP53, STK11, and EGFR) that most commonly occur in lung cancer; however, there are limited effective therapies to target these mutations. With this in mind, Moffitt Cancer Center performed an extensive genetic analysis of lung cancer specimens to unravel how mutations in the two of those genes (TP53 and STK11) contribute to the biology of lung cancer and patient outcomes.

12 Nov 2015

CWRU awarded two NIH grants to create pathology image informatics platform

Case Western Reserve University researchers have been awarded two grants totaling $3.16 million from the National Institutes of Health to create analytic software for managing, annotating, sharing and analyzing digital pathology imaging data.

12 Nov 2015

MD Anderson study reveals why chemotherapy drugs not effective for many pancreatic cancer patients

A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many pancreatic cancer patients, and perhaps point to new approaches to treatment including enhancing gemcitabine's ability to stop tumor growth.

12 Nov 2015

Crucial change in single DNA base predisposes children to aggressive form of cancer

Pediatric oncology researchers have pinpointed a crucial change in a single DNA base that both predisposes children to an aggressive form of the childhood cancer neuroblastoma and makes the disease progress once tumors form.

12 Nov 2015

New progenitor cells differentiate into mature cell types, prevent risk of unwanted tumors

Human pluripotent stem cells (hPSC) can become any type of cell in the adult body, offering great potential in disease modeling, drug discovery and creating replacement cells for conditions ranging from cardiovascular to Alzheimer's disease.

11 Nov 2015

Biocept receives European patent covering antibody usage in capture of rare cells

Biocept, Inc., a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces that the European Patent Office has awarded the patent, "DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS," as announced in the European Bulletin dated November 11, 2015.

11 Nov 2015

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

10 Nov 2015

Research opens door for developing biomarker tests to detect cancers early

Biomarkers, which allow diseases to be diagnosed and staged based on relatively non-invasive blood tests, have been identified for several types of cancers, but for most cancers remain elusive. Now, research conducted at the RIKEN Center for Life Science Technologies in Japan and the Harry Perkins Institute of Medical Research in Australia has identified a large number of genes that are upregulated in many different types of cancer, opening the door for developing biomarker tests that could be used to detect cancers early, allowing for prompt treatment.

10 Nov 2015

Boston Scientific signs definitive agreement to acquire CeloNova's interventional radiology business

Boston Scientific has entered into a definitive agreement to acquire the interventional radiology portfolio of CeloNova Biosciences, a San Antonio-based developer of endovascular and interventional cardiology technologies.

10 Nov 2015

New findings reveal association between colorectal cancer and melanoma drug treatment

Veteran cancer reseacher Prof. Emeritus Alexander Levitzki of Hebrew University of Jerusalem says new findings show link between colorectal cancer and melanoma drug treatment knoqwn as "NT157" in two recently published studies in journal, "Ocogene."

10 Nov 2015

Researchers find greater genetic diversity among cancer cells than anticipated

The most rigorous genetic sequencing ever carried out on a single tumor reveals far greater genetic diversity among cancer cells than anticipated. Researchers from the University of Chicago and the Beijing Institute of Genomics estimate that the tumor, about 3.5 centimeters in diameter, contained more than 100 million distinct mutations within the coding regions of its genes—thousands of times more than expected.

10 Nov 2015

New method may extend use of noninvasive prenatal testing to detect chromosomal abnormalities

Researchers at the University of California, San Diego School of Medicine developed a method to expand the types of chromosomal abnormalities that noninvasive prenatal testing (NIPT) can detect. The study, published November 9 by Proceedings of the National Academy of Sciences, uses a semiconductor sequencing platform to identify small chromosomal deletions or duplications, such as occur in Cri du Chat Syndrome and DiGeorge Syndrome, with a simple blood test from the expectant mother.

10 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

NanoString Technologies, Inc.a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of its 3D Biology™ portfolio with the commercial launch of the nCounter® PanCancer Profiles, seven new gene expression panels each designed to interrogate a focused area of cancer biology including immuno-oncology.

9 Nov 2015

No progression in joint damage in 84% of psoriatic arthritis patients

Novartis announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, Cosentyx maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, United States.

9 Nov 2015

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

Novartis announced today late-breaking two year results for Cosentyx® (secukinumab) showing up to 80% of patients with ankylosing spondylitis (AS) had no radiographic progression in the spine on x-ray assessment. This is the first time that data on structural spinal progression in AS have been presented for an interleukin-17A (IL-17A) inhibitor.

9 Nov 2015

New tool could help identify patients most likely to benefit from chemoprevention

A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

6 Nov 2015

Specific gut bacteria can improve cancer immunotherapy, show studies

By introducing a particular strain of bacteria into the digestive tracts of mice with melanoma, researchers at the University of Chicago were able to boost the ability of the animal's immune systems to attack tumor cells. T

6 Nov 2015

Tumor News and Research

Loyola and Notre Dame researchers report promising new approaches to treating cancer

Moffitt Cancer Center study finds link between common gene mutations and tumor immune surveillance

CWRU awarded two NIH grants to create pathology image informatics platform

MD Anderson study reveals why chemotherapy drugs not effective for many pancreatic cancer patients

Crucial change in single DNA base predisposes children to aggressive form of cancer

New progenitor cells differentiate into mature cell types, prevent risk of unwanted tumors

Biocept receives European patent covering antibody usage in capture of rare cells

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

Research opens door for developing biomarker tests to detect cancers early

Boston Scientific signs definitive agreement to acquire CeloNova's interventional radiology business

New findings reveal association between colorectal cancer and melanoma drug treatment

Researchers find greater genetic diversity among cancer cells than anticipated

New method may extend use of noninvasive prenatal testing to detect chromosomal abnormalities

AACR rapid and dramatic responses in TRK fusion patients

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

No progression in joint damage in 84% of psoriatic arthritis patients

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

New tool could help identify patients most likely to benefit from chemoprevention

Specific gut bacteria can improve cancer immunotherapy, show studies

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News